Navigation Links
Trius Reports New Findings on Mechanisms of Antibiotic Resistance in MRSA
Date:9/13/2010

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) today reported  new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox®.  Hospital outbreaks of linezolid resistant cfr strains of methicillin resistant Staphylococcus aureus (MRSA) have been reported worldwide and increasing use of linezolid may promote further dissemination of this plasmid borne resistance gene. Two separate articles featuring discussion of these data have been published online ahead of print on September 13 in Antimicrobial Agents and Chemotherapy (AAC), a peer-reviewed journal of the American Society for Microbiology.

S. aureus that express the cfr gene possess ribosomes that are structurally altered in a way that inhibits the binding of first generation oxazolidinone antibiotics such as linezolid, as well as the binding of antibiotics of other classes, such as the pleuromutilins, phenicols, lincosamides, and streptogramins. Torezolid's potent activity is preserved against cfr strains of S. aureus due to its unique structural features.

"Recent outbreaks of cfr strains of MRSA have fueled concerns that this pathogen will inevitably proliferate given the broad usage of linezolid and generic antibiotics that select for the plasmid borne cfr resistance gene," said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius and corresponding author on the papers.  "The potent activity of torezolid against cfr-positive bacteria differentiates it as a true second generation oxazolidinone which may be a solution to emerging linezolid resistance."

The AAC manuscripts are available to subscribers ahead of print at: http://aac.asm.org/papbyrecent.dtl.

Structure-Activity Relationships of Diverse Oxazolidinones for Linezolid-Resistant Staphylococcus aureus Strains Possessing the cfr Methyltransferase Gene or Ribosomal  Mutations

Jeffrey B. Locke, John Finn, Mark Hilgers, Gracia Morales, Shahad Rahawi, Kedar GC, Juan Jose Picazo, Weonbin Im, Karen Joy Shaw, and Jeffrey L. Stein

Antimicrob. Agents Chemother. published ahead of print on 13 September 2010

Elevated Linezolid Resistance in Clinical Staphylococcus aureus cfr Isolates is Associated with Co-occurring Mutations in Ribosomal Protein L3

Jeffrey B. Locke, Gracia Morales, Mark Hilgers, Kedar GC, Shahad Rahawi, Juan José Picazo, Karen Joy Shaw, and Jeffrey L. Stein

Antimicrob. Agents Chemother. published ahead of print on 13 September 2010

The results in these AAC articles are also featured in two poster presentations given at this year's ICAAC conference on September 14 (posters C1-1431 and C1-1432; Session 170; 11:15AM – 1:15PM). Trius presented a total of 12 posters at ICAAC highlighting the latest findings from its antibiotic research programs, including preclinical research on antibiotics targeting Gyrase B/ParE and dihydrofolate reductase (DHFR). Copies of all posters are available on the Trius website at: http://www.triusrx.com/trius-therapeutics-news-posters-publications-year.php.  

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential benefits of torezolid phosphate. Risks that contribute to the uncertain nature of the forward-looking statements include: Trius' ability to obtain additional financing; the success and timing of Trius' preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; the performance of third-party manufacturers; changes in Trius' plans to develop and commercialize its product candidates; Trius' ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Trius' most recently filed SEC documents, including its Registration Statement on Form S-1 that was originally filed with the United States Securities and Exchange Commission on November 6, 2009, and the amendments thereto, and Trius' Form 10-Q for the quarter ended June 30, 2010, including those factors discussed under the caption "Risk Factors" in such filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trius undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius to Present at the Stifel Nicolaus Healthcare Conference
2. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
3. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
4. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
5. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
6. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
7. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
8. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
9. Trius Doses First Patient in Antibacterial Phase 2 Trial
10. PacificGMP Completes GMP Product Fill for Trius Therapeutics
11. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 20, 2017 ResMed (NYSE: RMD ), BMC ... Winter Haven, Florida ) today announced they have agreed on ... 3B will be permitted to sell their existing products in exchange ... settlement payment to 3B to close the Florida ... an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... 20, 2017  Today, during a plenary ... Pathways in Immunology, Growth Disorders and Cancer," ... INFI ) presented preclinical data for ... selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical data showed ... resistance to checkpoint inhibition by remodeling the ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, Renal ... report to their offering. ... The global clinical laboratory testing market is expected ... innovative solutions on the grounds of maximum efficiency and minimum error ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... ... International Protein, a company based out of Australia that focuses on developing ... trade show in Hilton Head, SC. , International Protein was founded by Christine ... of products that would elevate her fitness regime. At this ECRM trade show, Envall ...
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Mary Magdalene: Grace ... mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is ... who spent her career as an educator interacting with countless women who had little ...
(Date:1/20/2017)... ... ... account following a man who went on to support his country and serve the Lord. ... Haven, Florida and at the age of 5, his family moved to Pensacola Florida. In ... and got married right out of boot camp. , He and his wife raised ...
Breaking Medicine News(10 mins):